Interpace Biosciences, Inc.
OTC: IDXG0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Thomas W. Burnell
- Employees
- 111
- Headquarters
- Parsippany, United States
- IPO year
- 1998
- Market cap
- $47.1M
- Website
- https://www.interpace.com
Loading IDXG…
Loading profile data…Frequently asked questions about IDXG
What does Interpace Biosciences, Inc. (IDXG) do?
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, pow...
Where does IDXG trade?
Interpace Biosciences, Inc. (IDXG) trades on the Other OTC.
What sector is IDXG in?
Interpace Biosciences, Inc. (IDXG) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Interpace Biosciences, Inc.?
Thomas W. Burnell is the chief executive officer of Interpace Biosciences, Inc. (IDXG).
Where is Interpace Biosciences, Inc. headquartered?
Interpace Biosciences, Inc. is headquartered in United States.
Does IDXG pay a dividend?
Interpace Biosciences, Inc. (IDXG) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IDXG go public?
Interpace Biosciences, Inc. (IDXG) completed its initial public offering in 1998.